Direct detection of regional myocardial ischemia with technetium-99m nitroimidazole in rabbits

Journal of Nuclear Medicine

Volumn 39, Issue 4, 1998, Pages 598-607

  Weinstein, Howard ^a,b   Reinhardt, Christopher P ^a   Leppo, Jeffrey A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Ischemia; Myocardial tracers; Technetium 99m nitroimidazole

Indexed keywords

NITROIMIDAZOLE; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW VELOCITY; CORONARY ARTERY BLOOD FLOW; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AUTORADIOGRAPHY; CORONARY CIRCULATION; FLUORESCEINS; HEART; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NITROIMIDAZOLES; ORGANOTECHNETIUM COMPOUNDS; PHOTOGRAPHY; RABBITS; TIME FACTORS; TISSUE SURVIVAL;

EID: 0031947365     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Miller GG, Ngan-Lee J, Chapman JD. Intracellular localization of radioactively labelled misonidazole in EMT-6 tumor cells in vitro. Int J Radiatology Oncology Biol Phys 1982;8:741-744.
2. Adams GE, Stratford IJ. Hypoxia-mediated nitro-heterocyclic drugs in the radio-and chemotherapy of cancer: an overview. Biochem Pharmacol 1986;35:71-76.
3. Chapman JD. Current concepts in cancer: hypoxic sensitizers - implications for radiation therapy. N Engl J Med 1979;301:1429-1432.
4. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Rad Res 1987;111:292-304.
5. Rasey JS, Koh W-J, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Intl J Radiat Oncol Biol Phys 1989;17:985-991.
6. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981;43:546-550.
7. Franko AJ. Misonidazole and other hypoxia markers: metabolism and applications, Intl J Radiat Oncol Biol Phys 1986;12:1195-1202.
8. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-2137.
9. Shelton ME, Dence CS, Hwang D-R, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18-fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol 1990;16:477-485.
10. Shelton ME, Dence CS, Hwang D-R, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. J Nucl Med 1989;30: 351-358.
11. 3H]fluoromisonidazole in ischemic myocardium. J Nucl Med 1989;30:194-201.
12. Martin GV, Cerqueira MD, Caldwell JH, Rasey JS, Embree L, Krohn KA. Fluoromisonidazole. A metabolic marker of myocyte hypoxia. Circ Res 1990;67:240-244.
13. Linder KE, Chan Y-W, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnAO-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem 1994;37:9-17.
14. Shi Q-X, Dione DP, Singer MJ, et al. Technetium-99m nitroimidazole: a positive imaging agent for the detection of myocardial ischemia [Abstract]. Circulation 1993;88:I-249.
15. Dahlberg ST, Gilmore MP, Flood M, Leppo JA. Effect of hypoxia and low-flow ischemia on the myocardial extraction of technetium-99m-nitroimidazole [Abstract]. Circulation 1993;88:I-250.
16. Connelly CM, Vogel WM, Hernandez YM, Apstein CS. Movement of necrotic wavefront after coronary occlusion in rabbit. Am J Physiol 1982;243:H682-H690.
17. Miura T, Downey JM, Ooiwa H, et al. Progression of myocardial infarction in a collateral now deficient species. Jpn Heart J 1989;30:695-708.
18. Horneffer PPJ, Healy B, Gott VL, Gardner TJ. The rapid evolution of a myocardial infarction in an end-artery coronary preparation. Circulation 1987;76:V-39-V-42.
19. 201TI by quantitative dual tracer autoradiography and segmental tissue analysis. J Nucl Med 1995;36:1645-1653.
20. Chopra P, Sabherwal U, Histochemical and fluorescent techniques for detection of early myocardial ischemia following experimental coronary artery occlusion: a comparative and quantitative study. Angiology 1988;39:132-140.
21. Cox JL, McLaughlin VW, Flowers NC, Horan LG. The ischemic zone surrounding acute myocardial infarction. Its morphology as detected by dehydrogenase staining. Am Heart J 1968;76:650-659.
22. Shnitka TK, Nachlas MM. Histochemical alterations in ischemic heart muscle and early myocardial infarction. Am J Pathol 1963;42:507-527.
23. Reinhardt CP, Weinstein H, Wironen J, Leppo JA. Effect of triphenyl tetrazolium chloride staining on the distribution of radiolabeled pharmaceuticals. J Nucl Med 1993;34:1722-1727.
24. Hales JRS. Radioactive microsphere techniques for studies of the circulation. Clin Exp Pharm phys 1974:31-46.
25. Heymann MA, Payne BD, Hoffman JIE, Rudolph AM. Blood flow measurement with radionuclide-labeled particles. Prog Cardiovasc Dis 1977;20:55-79.
26. Connelly CM, Leppo JA, Weitzman PW, Vogel WM, Apstein CS. Effect of coronary occlusion and reperfusion on myocardial blood flow during infarct healing. Am J Physiol 1989;257:H365-H374.
27. Whitmore GF, Varghese AJ. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. Biochem Pharmacol 1986;35:97-103.
28. Biaglow JE, Varnes ME, Roizen-Towle L, et al. Biochemistry of reduction of nitro heterocycles. Biochem Pharmacol 1986;35:77-90.
29. 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration, Intl J Radiat Oncol Biol Phys 1984;10:1327-1331.
30. Franko AJ, Chapman JD, Koch CJ. Binding of misonidazole to EMT6 and V79 spheroids. Intl J Radiat Oncol Biol Phys 1982;8:737-739.
31. Kirsti Y, Liu Y, Tsuchida A, et al. Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am J Physiol 1994;267:H2383-H2390.
32. Martin GV, Biskupiak JE, Caldwell JH, Rasey JS, Krohn KA. Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. J Nucl Med 1993;34:918-924.
33. Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med 1992;33:2202-2208.
34. Morguet AJ, Munz DL, Klein HH, et al. Myocardial distribution of indium-111-antimyosin Fab and technetium-99m-sestamibi in experimental nontransmural infarction. J Nucl Med 1992;33:223-228.
35. Shi CQ-X, Sinusas AJ, Dione DP, et al. Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. J Nucl Med 1995;36:1078-1086.
36. 3H]misonidazole in cerebral ischemia. Stroke 1987;18:168-176.
37. Okada RD, Jacobs ML, Daggett WM, et al. Thallium-201 kinetics in nonischemic canine myocardium. Circulation 1982;65:70-77.
38. Eckelman WC. Diagnostic isotopes: prospects for improved agents. Invest Radiol 1989;24:252-254.